SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:
NGEN), developer of advanced diagnostic products, announced today that it
has expanded its product portfolio to include the MGB Alert(TM) ENV
real-time PCR reagent, designed to detect sequences associated with
enteroviruses. Prevalent in summer and fall, enterovirus infections cause a
wide spectrum of diseases and are the most common cause of aseptic
"According to the Centers for Disease Control, enteroviruses cause an
estimated 10 to 15 million symptomatic cases a year in the United States,"
said Howard C. Birndorf, Nanogen chairman and chief executive officer.
"Enterovirus testing constitutes a segment of the infectious disease
molecular diagnostics market, which is expected to reach $2.3 billion by
"Detection of viral infections by real-time PCR is typically faster,
more sensitive and more specific than through other methods," said
Birndorf, "and should help reduce the healthcare costs associated with
enteroviral infections." Aseptic meningitis cases account for tens of
thousands of hospitalizations every year.
George E. Buck, chief of microbiology at Norton Healthcare in
Louisville, KY, finds the MGB Alert ENV product to be "very sensitive and
easy to use. Physicians at our hospital rely on our results to help them
diagnose these infections."
Nanogen's MGB Alert Enterovirus analyte specific reagent (ASR), like
all MGB Alert products, utilizes novel detection chemistry claimed in U.S.
Patent 7,045,610, issued to Nanogen May 16. The '610 patent, "Modified
Oligonucleotides for Mismatch Discrimination," claims the use of modified
bases to improved hybridization-based diagnostic assays.
The patented chemistry is employed in most of the company's ASRs and
research products, enabling laboratories to develop multiple assays with
universal parameters, which increases the efficiency and throughput of
clinical testing. The super bases (Super A(TM), Super T(TM), Super G(TM)
and Super N(TM)) and MGB technology described in '610 allow the use of
shorter probes with increased sensitivity to mismatches, which have proved
essential for detecting short conserved sequences of enteroviruses as well
as other pathogens.
"Specifically, '610 allows Nanogen to deliver real-time PCR probe and
primer designs for targets that would be otherwise intractable," said
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose,
and ultimately help treat disease. The company's products include real-time
PCR reagents, the NanoChip(R) electronic microarray platform and a line of
rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering
research involving nanotechnology holds the promise of miniaturization and
continues to be supported for its potential for diagnostic and biodefense
applications. For additional information please visit Nanogen's website at
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements,
including whether patents owned or licensed by Nanogen will be developed
into products, whether the patents owned by Nanogen offer any protection
against competitors with competing technologies, whether products under
development can be successfully developed and commercialized, whether
results reported by our customers or partners can be identically
replicated, and other risks and uncertainties discussed under the caption
"Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
Form 10-Q most recently filed with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof. Nanogen
disclaims any intent or obligation to update these forward-looking
SOURCE Nanogen, Inc.